Clinical trial
A Randomized, Multicenter, Phase II Open-label Study of the Efficacy and Safety of Pyrotinib + Vinorelbine vs. Treatment of Physician's Choice in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
NCT03997539 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multicenter, Phase II Open-label Study of the Efficacy and Safety of Pyrotinib + Vinorelbine vs. Treatment of Physician's Choice in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 15, 2019
- Completion date
- December 30, 2021
- Enrollment
- 256 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic breast cancer